ML&P Blog: Our insight into current issues

Medicines Law & Policy periodically will post timely analysis and insight into current events related to intellectual property and innovation policy as they impact on access to medicines. These posts are listed below. We also have a newsletter for those interested in being notified when new articles are posted.

Latest Blog Posts

WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument

In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...

Treatment for cystic fibrosis added to Essential Medicines List by the World Health Organization: A victory for campaigners, though prices still ‘toxic’

The World Health Organization today announced it has added the cystic fibrosis combination treatment elexacaftor + tezacaftor + ivacaftor (brand name Trikafta) to its...

FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending HIV

On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...

Transfer of technology and know-how for the production of pandemic-related health products in the WHO Pandemic Agreement: The proverbial half glass 

A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot During...

World Health Assembly adopts the Pandemic Agreement

"I see no objection, the resolution is adopted," said Teodoro J. Herbosa, Secretary of Health of the Philippines and President of the 78th World...

The People vs. AbbVie

Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

The Pandemic Agreement is here

In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...

Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development

This is an excerpt from a longer report on AI, medicines development and the patent system. Download the full report here (or by clicking...

Expanding local production is essential for pandemic preparedness. It requires, however, transfer of technology.

Madam co-chairs, delegates,  This very week, from 7 to 9 April the 3rd World Local Production Forum is taking place in Abu Dhabi. Actions towards...

Respect for intellectual property law includes respecting the flexibilities it contains to protect the public interest: ML&P’s opening statement to the INB

Thank you for the opportunity to speak. And for the latest draft of the pandemic agreementshared with us on 26 March. In particular, we...

Newsletter

Never miss a post! Sign up for ML&P's newsletter.

Posts by topic

Year-End Wrap-Ups

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Wrapping up 2022 with some noteworthy medicines, law and policy events

Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy. Also in 2022, Covid-19 remained a central...

Wrapping up 2021 – some noteworthy medicines law and policy events

Welcome to the annual end of the year blog, our highly biased overview of noteworthy events in the field of medicines law and policy....